Arcellx Inc
ACLX
Company Profile
Business description
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Contact
800 Bridge Parkway
Suite A
RedwoodCA94065
USAT: +1 240 327-0603
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
209
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.90 | 0.10 | 0.00% |
| CAC 40 | 8,045.80 | 121.93 | -1.49% |
| DAX 40 | 23,815.75 | 389.61 | -1.61% |
| Dow JONES (US) | 47,954.74 | 784.67 | -1.61% |
| FTSE 100 | 10,413.94 | 153.71 | -1.45% |
| HKSE | 25,321.34 | 71.86 | 0.28% |
| NASDAQ | 22,748.99 | 58.50 | -0.26% |
| Nikkei 225 | 55,278.06 | 1,032.52 | 1.90% |
| NZX 50 Index | 13,538.61 | 79.28 | -0.58% |
| S&P 500 | 6,830.71 | 38.79 | -0.56% |
| S&P/ASX 200 | 8,940.30 | 3.10 | -0.03% |
| SSE Composite Index | 4,108.57 | 26.09 | 0.64% |